THE BAD NEWS for medical societies is that long-standing general (not event-specific) support seems to be on the decline in the current regulatory environment. The good news is that pharmaceutical companies are shifting their attention to CME meetings. But obtaining commercial support for any initiative, including meetings, is an increasingly complicated process.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments
